Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2019 Dec 12;47(4):947–957. doi: 10.1007/s00259-019-04530-1

Fig. 3.

Fig. 3

Comparison of ΔSUVmax% between 177Lu-DOTATATE group and 177Lu-DOTA-EB-TATE groups (group B-D combined). (A) In all qualified lesions, ΔSUVmax% in 177Lu-DOTATATE group is 5.4 ± 45.9 and in 177Lu-DOTA-EB-TATE groups is −5.2 ± 49.0 (P=0.387); (B) Selecting comparable baseline SUVmax ranging from 15 to 40, mean ΔSUVmax% in 177Lu-DOTATATE group is 8.4 ± 48.8, in177Lu-DOTA-EB-TATE group is −19.0 ± 21.5 (P=0.045).